WHAT IS CLAIMED IS:

1. A method of treating migraine in a subject in need thereof, the method comprising the step of administering to the subject an amount of a glucocorticoid receptor antagonist effective to treat migraine in the subject,

(i) with the proviso that the subject is not otherwise in need of treatment with a glucocorticoid receptor antagonist, and

(ii) with the proviso that the subject is not also being treated with triptans nor any other pharmaceutically prescribed entity that is predominantly metabolized by a cytochrome P450-3A4 isoenzyme.

2. The method of claim 1, wherein the subject is a human.

3. The method of claim 1, wherein the treatment for migraine is administered prophylactically.

4. The method of claim 3, wherein the treatment for migraine is administered daily.

5. The method of claim 1, wherein the treatment for migraine is administered during the course of a migraine attack.

6. The method of claim 1, wherein the glucocorticoid receptor antagonist comprises a steroidal skeleton with at least one phenyl-containing moiety in the 11-beta position of the steroidal skeleton.

7. The method of claim 6, wherein the phenyl-containing moiety in the 11-beta position of the steroidal skeleton is a dimethylaminophenyl moiety.

8. The method of claim 7, wherein the glucocorticoid receptor antagonist is mifepristone.

9. The method of claim 7, wherein the glucocorticoid receptor antagonist is selected from the group consisting of 11β-(4-dimethylaminoethoxyphenyl)-17α-propynyl-17β-hydroxy-4,9-estradien-3-one and 17β-hydroxy-17α-19-(4-methylphenyl)androsta-4,9(11)-dien-3-one.

10. The method of claim 1, wherein the glucocorticoid receptor antagonist is selected from the group consisting 4α(*S*)-Benzyl-2(*R*)-prop-1-ynyl-1,2,3,4,4α,9,10,10α(*R*)-octahydro-phenanthrene-2,7-diol and 4α(*S*)-Benzyl-2(*R*)-chloroethynyl-1,2,3,4,4α,9,10,10α(*R*)-octahydro-phenanthrene-2,7-diol.

11. The method of claim 1, wherein the glucocorticoid receptor antagonist is (11β,17β)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one.

12. The method of claim 1, wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about .5 to about 35 mg per kilogram of body weight per day.

13. The method of claim 12, wherein the glucocorticoid receptor antagonist is administered in a daily amount of between about 5 to about 15 mg per kilogram of body weight per day.

14. The method of claim 1, wherein the administration is once per day.

15. The method of claim 1, wherein the mode of administration is by a transdermal application, by a nebulized suspension, or by an aerosol spray.

16. The method of claim 1, wherein the mode of administration is oral.

17. A kit for treating migraine in a subject,

the kit comprising:

(i) a specific glucocorticoid receptor antagonist; and,

(ii) an instructional material teaching the indications, dosage and schedule of administration of the glucocorticoid receptor antagonist to a patient with the migraine.

18. The kit of claim 17, wherein the instructional material indicates that the glucocorticoid receptor antagonist can be administered in a daily amount of about .5 mg to about 35 mg per kilogram of body weight per day.

19. The kit of claim 17, wherein the instructional material indicates that the glucocorticoid receptor antagonist can be administered in a daily amount of about 5 to about 15 mg per kilogram of body weight per day.

20. The kit of claim 17, wherein the glucocorticoid receptor antagonist is mifepristone.

21. The kit of claim 17, wherein the mifepristone is in a form that permits dosage by way of an aerosol spray.